- Open Access
Interactions among genes in the ErbB-Neuregulin signalling network are associated with increased susceptibility to schizophrenia
© Benzel et al; licensee BioMed Central Ltd. 2007
- Received: 18 May 2007
- Accepted: 28 June 2007
- Published: 28 June 2007
Evidence of genetic association between the NRG1 (Neuregulin-1) gene and schizophrenia is now well-documented. Furthermore, several recent reports suggest association between schizophrenia and single-nucleotide polymorphisms (SNPs) in ERBB4, one of the receptors for Neuregulin-1. In this study, we have extended the previously published associations by investigating the involvement of all eight genes from the ERBB and NRG families for association with schizophrenia.
Eight genes from the ERBB and NRG families were tested for association to schizophrenia using a collection of 396 cases and 1,342 blood bank controls ascertained from Aberdeen, UK. A total of 365 SNPs were tested. Association testing of both alleles and genotypes was carried out using the fast Fisher's Exact Test (FET). To understand better the nature of the associations, all pairs of SNPs separated by ≥ 0.5 cM with at least nominal evidence of association (P < 0.10) were tested for evidence of pairwise interaction by logistic regression analysis.
42 out of 365 tested SNPs in the eight genes from the ERBB and NRG gene families were significantly associated with schizophrenia (P < 0.05). Associated SNPs were located in ERBB4 and NRG1, confirming earlier reports. However, novel associations were also seen in NRG2, NRG3 and EGFR. In pairwise interaction tests, clear evidence of gene-gene interaction was detected for NRG1-NRG2, NRG1-NRG3 and EGFR-NRG2, and suggestive evidence was also seen for ERBB4-NRG1, ERBB4-NRG2, ERBB4-NRG3 and ERBB4-ERBB2. Evidence of intragenic interaction was seen for SNPs in ERBB4.
These new findings suggest that observed associations between NRG1 and schizophrenia may be mediated through functional interaction not just with ERBB4, but with other members of the NRG and ERBB families. There is evidence that genetic interaction among these loci may increase susceptibility to schizophrenia.
- Pairwise Interaction
- Genotypic Test
- Allelic Test
- ErbB Family Member
Schizophrenia is a complex psychiatric disorder which affects 0.5–1% of the world wide adult population. A number of putative schizophrenia susceptibility genes have been identified recently [1, 2]. Genomewide linkage analysis on large Icelandic pedigrees showed evidence for linkage with an initial LOD score of 3 on chromosome 8p13, which led to the identification of the Neuregulin-1 gene (NRG1) as a potential genetic risk factor (O.R. = 2) for schizophrenia . The association was confirmed in a large Scottish case control data set , and both studies indicated a core haplotype (HAPICE) as the DNA variation carrying most of the risk for schizophrenia. Subsequently, 15 published studies in schizophrenia data sets of various Asian and Caucasian ethnic backgrounds have detected association in NRG1 SNPs or haplotypes, while only four studies were not able to replicate the association (see  and  for a comprehensive review). The association studies reported thus far strongly suggest a true effect of NRG1 as a susceptibility gene for schizophrenia. However, some caution should be exercised before calling NRG1 a true "schizophrenia gene" due to the lack of a known functional effect of the identified NRG1 variants, the allelic heterogeneity reported across several studies and the multiple SNPs and haplotypes analysed in different studies. Nonetheless, several recent publications report an association between schizophrenia and ErbB4, one of the receptors for NRG1 [7–9]. This provides indirect evidence supporting NRG1 association with schizophrenia and a role for aberrant neuregulin signalling in this disorder.
The Neuregulin-ErbB signalling network is involved in a multitude of processes in the developing and adult brain. Neuregulins for example promote neuronal migration and differentiation, regulate the expression of neurotransmitter receptors, influence glial proliferation, survival and differentiation and play a role in synaptic plasticity.
The neuregulins (NRG) are cell-cell signalling proteins that are ligands for receptor tyrosine kinases of the ErbB family. Whereas NRG1 is known to play essential roles in nervous system and heart development, as well as in the adult brain (see above), less is known about the other members of the NRG gene family, NRG2, -3 and -4 [10, 11].
Ligand binding to the extracellular domain of ErbB family members leads to receptor homo-and heterodimerisation and activation of various intracellular signalling pathways such as the Ras-Raf-MAPK and the PI-3 Kinase pathways (reviewed in ).
In order to investigate the involvement of neuregulin pathway genes in schizophrenia, beyond the previously published association with NRG1 and ERBB4, we have tested all eight genes from the ERBB and NRG families for association with schizophrenia. We have investigated both single genes and gene-gene interactions, using a collection of schizophrenia cases and blood bank controls from Aberdeen, Scotland.
Caucasian cases were ascertained in Aberdeen, Scotland. All have a basic diagnosis of schizophrenia or schizoaffective disorder according to the Operational Criteria Checklist (OPKRIT). 285 of the cases were male; 111 were female. The mean recruitment age was 44 yr with a standard deviation of 14 yr.
Controls were ascertained as a series of anonymous blood donors from Aberdeen, Scotland. Due to subject anonymity, characteristics such as schizophrenia- status, age and ethnic group could not be determined. However at the time of sample collection, the Aberdeen Blood Transfusion Service made a concerted effort to exclude any non-Caucasian samples. At the time of this study, non-Caucasians constituted around 2% of the Aberdeen population but a lower percentage of Aberdeen blood donors. 724 control subjects were male; 618 were female. Informed consent was obtained for all subjects involved in this study.
As calculated by the power equations of Risch and Teng , under a multiplicative model of association, a sample of 400 cases and 1300 controls has 80% power to detect disease association at an α = 0.05 significance level for SNPs having a genotypic relative risk of 1.5  and susceptibility allele frequencies between 0.07 and 0.9.
Polymorphism selection and genotyping
SNPs in potentially functional gene regions included in the present study.
Amino acid change
Polymorphism in genes in the families NRG and ErbB investigated in this study.
No. of analysable SNPs
No. of SNPs with p < 0.101
No. of SNPs with p < 0.051
Genotyping was performed using a modification of the single base chain extension assay previously described , at GlaxoSmithKline, UK. A SNP passed QC if over 80% of genotype calls were successful.
All SNPs were tested for departure from Hardy Weinberg equilibrium (HWE) in controls using a chi squared test with one degree of freedom. This test compares the expected genotype frequencies calculated from the allele frequencies, with observed genotype frequencies. A departure from HWE in controls may indicate errors in the data.
Association testing of both alleles and genotypes was carried out using the 'PROC FREQ' fast Fisher's Exact Test (FET) procedure in the statistical software package SASv8.2 (SAS Institute Inc., Cary, NC, USA). The Fast Fisher's Exact Test computes exact P-values for general contingency tables using the network algorithm developed by . The network algorithm provides substantial advantages over direct enumeration and is rapid and accurate. The exact test is used in preference to the asymptotic chi-square P-value as it is more accurate at loci where the minor allele frequency is low.
where x1, x2, z1 and z2 are variables determined by the genotype under consideration, and μ, a1, a2, d1, d2, i aa , i ad , i da and i dd are parameters to be estimated. Here, genotypes at two SNPs are being modelled and, for each of the 9 possible genotype combinations at the two SNPs, p is the proportion of subjects with the genotype who are cases and (1-p) is the proportion of subjects with the genotype who are controls. The first five terms in the equation represent the effects of the two SNPs on log(p/(1-p)) if there is no statistical interactions between the two SNPs. A non-zero value for one or more of the remaining four coefficients (i aa , i ad , i da , i dd ) indicates the presence of interaction. Statistical significance was assessed by a likelihood ratio test, comparing the full model above with a reduced model in which the last four terms are absent (i.e. in which the coefficients i aa , i ad , i da and i dd are all set to zero).
A significant interaction effect in the logistic regression analysis indicates that the combined effect of the two SNPs is significantly different from the sum of their individual effects. Pair-wise interactions may be of three types, namely 'and', 'or' and 'exclusive or', defined as follows. In an 'and' relationship, the effect of having the risk-enhancing genotypes at both SNP loci is larger than the sum of the single-locus effects. In an 'or' relationship, the effect of having the risk-enhancing genotype at both loci is smaller than the sum of the single-locus effects. In the final type of interaction, named 'exclusive or', the effect of having the risk-enhancing genotype at both loci is smaller than that of having a risk-enhancing genotype at only one locus. For each SNP pair, each of these configurations gives rise to a contingency table, classified by genotype group (risk-enhancing or risk-reducing) and phenotype (case or control). These contingency tables were evaluated, and the configuration with the lowest P-value for association with the phenotype was identified. This configuration indicated the type of interaction between the two loci in question.
Although controls were selected from the same geographic area as the cases, a test was conducted to determine the presence of any latent population stratification. The lambda statistic of Devlin et al. , calculated on 4,250 SNPs distributed over the whole genome, showed no evidence of stratification (population heterogeneity, overdispersion: Genotypic exact lambda = 1.061, Allelic exact lambda = 1.000), indicating that no genomic-control adjustment is required when performing tests of genotypic and allelic association on these subjects.
Of 374 SNPs submitted for genotyping, 3 were dropped from analysis due to monomorphism in cases and controls, and another 6 were dropped due to departure from Hardy-Weinberg Equilibrium (P < 0.001). Among the remaining SNPs, the proportion of individuals successfully genotyped ranged from 0.804 to 0.99, with a median of 0.97. A subset of the individuals studied was genotyped in duplicate, giving a total of 14,323 duplicate genotypes. Of these, only 2 (= 0.014%) were inconsistent. The 365 SNPs retained, located in 8 genes, were subjected to single-point analysis. The number of SNPs per gene is given in Table 2. The median frequency of the minor allele among the SNPs analysed was 22.9 %, but there were 35 SNPs (9.6% of those analysed) for which the minor allele frequency was less than 5%. These SNPs, selected prior to the availability of the HapMap , are less informative than the others; however, as they do provide some additional information they were retained in the analysis.
Both allelic and genotypic tests of association were conducted. Detailed results are provided in Additional file 1. Significant results (P < 0.05) were observed in five genes, namely NRG1, NRG2, NRG3, EGFR and ERBB4. These confirmed previous findings on NRG1 and ERBB4 and suggest possible involvement also of NRG2, NRG3 and EGFR. Borderline evidence of association (P < 0.10) was observed for one SNP in ERBB2. Haplotypic tests of association (not shown) provided similar results to the single-point results described here. If none of the 365 single SNPs were associated with the disease status (the null hypothesis), we would expect 18 SNPs to be significant at the 0.05 level and 37 SNPs to be significant at the 0.10 level on an allelic test. For the allelic test there were 34 SNPs significant at the 0.05 level (9.3%) and 59 SNPs significant at the 0.10 level (16.2%). For the genotypic test there were 24 SNPs significant at the 0.05 level (6.6%) and 62 SNPs significant at the 0.10 level (17.0%). This excess of significantly associated SNPs, beyond the numbers expected by chance when accounting for the multiple tests, provides evidence that some of these associations are real.
Interaction analysis results
As summarised in Table 2, 79 SNPs were identified which had a P-value from an allelic or genotypic test that was less than 0.10 (details are given in Additional file 2). These SNPs were contained in the 6 genes considered above, namely NRG1, NRG2, NRG3, EGFR, ERBB2, and ERBB4. All pairs of these SNPs that are at least 0.5 cM apart on an interpolated Decode genetic map  were tested for interaction effects in a logistic regression interaction analysis.
A total of 2640 statistical tests for pair-wise interactions were performed (details of results are given in Additional file 2). Of these, 212 were significant at the 5% level: that is 8.03% of all tests were significant compared to 132 (= 5% of 2640) expected by chance if the null hypothesis of no interaction were true for all pairs of SNPs tested. If all the tests performed were mutually independent the probability that 212 or more would be significant by chance is 2.575 × 10-11 (P(R ≥ 212) where R~binomial(N = 2640, p = 0.05)). The true probability of such an outcome is certain to be larger, due to non-independence among the tests: nevertheless, this result provides convincing evidence that some of the observed interactions are real. The significance levels presented here are not adjusted for multiple testing: a Bonferroni correction would be inappropriate due to non-independence among the tests, and the multiple-testing issue is addressed by the comparison of observed and expected numbers of significant tests presented above. None of the significant results obtained would survive the Bonferroni correction.
Percentages of pair-wise interactions that were significant (P < 0.05), classified by the gene(s) in which the interacting SNPs lie. Gene combinations in which there are substantially more significant interactions than the 5% expected by chance are indicated in bold. The counts that contribute to each percentage are also shown in parentheses as a fraction. The presence of "-" in the table indicates that no pairs of SNPs in this gene are 0.5 cM apart.
In this manuscript we present confirmation of earlier published associations between schizophrenia and the genes NRG1 and ERBB4. We build a new, compelling picture of pathway involvement by showing that associations exist with additional gene family-members, namely EGFR, NRG2, and NRG3. Lastly, we present statistical evidence of gene epistasis, consistent with a highly complex biological pathway of schizophrenia susceptibility. This is the first time that the roles and inter-relationships of the ERBB and NRG gene families as a whole have been investigated in relation to schizophrenia and our approach sets a precedent in the investigation of common complex diseases.
Clear evidence for gene-gene interaction was detected for gene combinations NRG1-NRG2, NRG1-NRG3 and EGFR-NRG2, and suggestive evidence was also seen for ERBB4-NRG1, ERBB4-NRG2, ERBB4-NRG3 and ERBB4-ERBB2. Evidence of intragenic interaction was seen for SNPs in ERBB4. Of the 2640 tests for pair-wise interaction, 212 were significant at the 5% level, which is substantially more than the 131 expected by chance. This large number of low P- values may be partly explained by non-independence among tests. However, it may also indicate that some of the 79 SNPs studied interact to modulate susceptibility to schizophrenia.
Numerous studies have investigated the association between schizophrenia and NRG1 (reviewed in ). A comparison of the associations generated in the current study with those previously published shows good agreement. Associations that we observed at the 5' region of NRG1 overlap with those found by Stefansson et al. [3, 4], Corvin et al. , Li et al. , Zhao et al.  and Petryshen et al. . Similarly, the associations we observed at the 3' end of the gene overlap with those found by Yang et al. , Li et al. , Petryshen et al.  and Lachmann et al. . Two polymorphisms in our study directly replicate these associations: the putatively functional SNP rs3924999 was found to be associated with schizophrenia in a Han Chinese family study conducted by Yang et al. . This SNP was also tested in a Caucasian study of 136 families by Duan et al. , but was not significant. Rs2466049 was significant as part of a haplotype found in a Caucasian family by Petryshen et al. .
For the ERBB4 gene, four polymorphisms (rs3748962, rs839523, rs2054617 and rs6435711) screened in this study were also analysed by Silberberg et al. . However, none of the individual SNP associations observed in the previous study was replicated here. As no underlying functional variant has been identified for ERBB4, this lack of association at the SNP level is unsurprising and is consistent with a heterogeneous haplotypic background across studies. It is worth noting also that non-coding polymorphisms might lead to dysregulation of ErbB4 expression levels, a hypothesis corroborated by the Silberberg et al.  study, which found enhanced expression of the ERBB4 Jm-a CYT-1 isoform (one of four splice variants, see ) in schizophrenic patients. The altered balance of ErbB4 isoforms could lead to variations in homo- and heterodimer formation and thus in downstream signalling pathways.
In addition to providing further evidence of NRG1 and ERBB4 associations to schizophrenia, our study is the first to suggest possible involvement of three additional genes from the NRG and ERBB gene families, i.e. NRG2, NRG3 and EGFR (ERBB1). It is interesting to note that we only detected evidence for association of NRG genes which are expressed in the central nervous system, namely NRG1, NRG2 and the nervous-system-specific NRG3 , whereas NRG4, which is mainly expressed in pancreas and absent from the brain  was not found to be associated to schizophrenia.
To our knowledge, an association of EGFR to schizophrenia has not previously been investigated. Association of a polymorphism in EGF (one of the six EGFR ligands, Fig. 1) with schizophrenia was reported in Finnish men , but not replicated in a Japanese population . Further support for a possible role of EGF and EGFR in the disease comes from findings of abnormal expression of these genes in the forebrain and serum of schizophrenic patients . EGFR is usually omitted in reviews on NRG-ERBB signalling, although it is well-established that ErbB4 can interact with and cross-phosphorylate EGFR upon neuregulin-binding [36–39]. Furthermore, EGFR and ERBB4 show partially overlapping temporal and spatial mRNA expression in several brain areas, such as cortex, striatum, cerebellum and hippocampus, and are coexpressed in GABAergic interneurons [40, 41]. Therefore, it is very likely that EGFR/ErbB4 heterodimers mediate important functions in the developing and adult central nervous system in vivo. Whilst we limited this study to the NRG and ERBB gene families, it would be interesting to investigate association of the additional EGFR and ErbB4 ligands (see Fig. 1).
The significant gene-gene interactions reported in this study support our hypothesis of pathway involvement in schizophrenia. These genes have related functions and, for example, the NRG1-NRG2 and NRG1-NRG3 interactions may suggest competition between these ligands for a receptor. The NRG2-EGFR interaction is superficially more difficult to explain since NRG2 is a ligand for ErbB3 and ErbB4 and does not usually recognize EGFR directly or with high affinity [42–44]. However, a recent study reports that a single amino acid change in the EGFR ligand-binding domain dramatically increases the receptor affinity for NRG2β which can then induce potent stimulation of EGFR signalling . The interactions within the ERBB4 gene suggest that combinations of particular genotypes may result in modified receptor activity, leading to altered risk of schizophrenia.
Such suggestions concerning possible mechanisms of interaction remain speculative until the reality of these interactions has been established biologically and the effect of each two-locus genotype on the phenotype is understood. A follow-up study currently underway, using independent cases and controls, will clarify which of these interactions can be replicated and may generate further hypotheses regarding the nature of the interactions. It will be interesting also to investigate whether observed associations or their interactions correspond to particular phenotypically defined patient sub-groups. The strong evidence of genetic associations and interactions reported here provides ample justification for such an enquiry.
This study confirms previously published associations between schizophrenia and NRG1 and ERBB4, and points to three other members of the NRG and ERBB gene families (EGFR, NRG2 and NRG3) as potential schizophrenia susceptibility genes. Furthermore, the study presents evidence for inter- and intragenic pair-wise interaction between loci in genes of both families (NRG1-NRG2, NRG2-EGFR, NRG1-NRG3 and ERBB4-ERBB4). These extensive genetic inter-relationships observed among ligands and receptors of the ERBB and NRG gene families reflect the complexity of their interactions at the molecular level. The influence of so many closely related genetic factors on the potential development of disease pathophysiology has rarely, if ever, been demonstrated before and may partially explain the difficulty in arriving at an overarching genetic hypothesis of the etiology of schizophrenia. In future studies, it will be important to replicate our new findings in an independent cohort and to understand the underlying biological mechanisms of the single-locus associations as well as the interactions among different loci.
The authors wish to acknowledge the patients and blood donors who contributed to this study. Thanks are also due to members of the GSK Genetic Sample Management and Genotyping groups; also Matt Nelson, Pierandrea Muglia, Paul Skelding and Nicola Foote for their helpful contributions in the writing of this paper.
- Owen MJ, Craddock N, O'Donovan MC: Schizophrenia: genes at last? [Review]. Trends in Genetics. 2005, 21: 518-525. 10.1016/j.tig.2005.06.011.View ArticlePubMedGoogle Scholar
- Harrison PJ, Weinberger DR: Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence [Review]. Molecular Psychiatry. 2005, 10: 40-68. 10.1038/sj.mp.4001558.View ArticlePubMedGoogle Scholar
- Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, Brynjolfsson J, Gunnarsdottir S, Ivarsson O, Chou TT, Hjaltason O, Birgisdottir B, Jonsson H, Gudnadottir VG, Gudmundsdottir E, Bjornsson A, Ingvarsson B, Ingason A, Sigfusson S, Hardardottir H, Harvey RP, Lai D, Zhou M, Brunner D, Mutel V, Gonzalo A, Lemke G, Sainz J, Johannesson G, Andresson T, Gudbjartsson D, Manolescu A, Frigge ML, Gurney ME, Kong A, Gulcher JR, Petursson H, Stefansson K: Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet. 2002, 71: 877-892. 10.1086/342734.PubMed CentralView ArticlePubMedGoogle Scholar
- Stefansson H, Sarginson J, Kong A, Yates P, Steinthorsdottir V, Gudfinnsson E, Gunnarsdottir S, Walker N, Petursson H, Crombie C, Ingason A, Gulcher JR, Stefansson K, St Clair D: Association of neuregulin 1 with schizophrenia confirmed in a Scottish population. Am J Hum Genet. 2003, 72: 83-87. 10.1086/345442.PubMed CentralView ArticlePubMedGoogle Scholar
- Tosato S, Dazzan P, Collier D: Association between the neuregulin 1 gene and schizophrenia: a systematic review. Schizophr Bull. 2005, 31: 613-617. 10.1093/schbul/sbi043.View ArticlePubMedGoogle Scholar
- Harrison PJ, Law AJ: Neuregulin 1 and Schizophrenia: Genetics, Gene Expression, and Neurobiology. Biol Psychiatry. 2006, 60: 132-140.View ArticlePubMedGoogle Scholar
- Norton N, Moskvina V, Morris DW, Bray NJ, Zammit S, Williams NM, Williams HJ, Preece AC, Dwyer S, Wilkinson JC, Spurlock G, Kirov G, Buckland P, Waddington JL, Gill M, Corvin AP, Owen MJ, O'Donovan MC: Evidence that interaction between neuregulin 1 and its receptor erbB4 increases susceptibility to schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2006, 141: 96-101.View ArticleGoogle Scholar
- Silberberg G, Darvasi A, Pinkas-Kramarski R, Navon R: The involvement of ErbB4 with schizophrenia: association and expression studies. Am J Med Genet B Neuropsychiatr Genet. 2006, 141: 142-148.View ArticleGoogle Scholar
- Nicodemus KK, Luna A, Vakkalanka R, Goldberg T, Egan M, Straub RE, Weinberger DR: Further evidence for association between ErbB4 and schizophrenia and influence on cognitive intermediate phenotypes in healthy controls. Molecular Psychiatry. 2006, 11: 1062-1065. 10.1038/sj.mp.4001878.View ArticlePubMedGoogle Scholar
- Falls DL: Neuregulins: functions, forms, and signaling strategies. Exp Cell Res. 2003, 284: 14-30. 10.1016/S0014-4827(02)00102-7.View ArticlePubMedGoogle Scholar
- Talmage DA, Role LW: Multiple personalities of neuregulin gene family members. J Comp Neurol. 2004, 472: 134-139. 10.1002/cne.20091.PubMed CentralView ArticlePubMedGoogle Scholar
- Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001, 2: 127-137. 10.1038/35052073.View ArticlePubMedGoogle Scholar
- Risch N, Teng J: The relative power of family-based and case-control designs for linkage disequilibrium studies of complex human diseases - I. DNA pooling. Genome Research. 1998, 8: 1273-1288.PubMedGoogle Scholar
- Risch N, Merikangas K: The future of genetic studies of complex human diseases. Science. 1996, 273: 1516-1517. 10.1126/science.273.5281.1516.View ArticlePubMedGoogle Scholar
- Taylor JD, Briley D, Nguyen Q, Long K, Iannone MA, Li MS, Ye F, Afshari A, Lai E, Wagner M, Chen J, Weiner MP: Flow cytometric platform for high-throughput single nucleotide polymorphism analysis. Biotechniques. 2001, 30: 661-669.PubMedGoogle Scholar
- CR M, NR P: A network algorithm for performing Fisher's Exact Test in r ×c contingency tables. J Am Stat Assoc. 1983, 78: 427-434. 10.2307/2288652.Google Scholar
- The R Project for Statistical Computing. 2003, http://www.r-project.org/
- Cordell HJ: Epistasis: what it means, what it doesn't mean, and statistical methods to detect it in humans. Hum Mol Genet. 2002, 11: 2463-2468. 10.1093/hmg/11.20.2463.View ArticlePubMedGoogle Scholar
- Devlin B, Roeder K, Wasserman L: Genomic control, a new approach to genetic-based association studies. Theoretical Population Biology. 2001, 60: 155-166. 10.1006/tpbi.2001.1542.View ArticlePubMedGoogle Scholar
- Altshuler D, Brooks LD, Chakravarti A, Collins FS, Daly MJ, Donnelly P: A haplotype map of the human genome. Nature. 2005, 437: 1299-1320. 10.1038/nature04226.View ArticleGoogle Scholar
- Kong A, Gudbjartsson DF, Sainz J, Jonsdottir GM, Gudjonsson SA, Richardsson B, Sigurdardottir S, Barnard J, Hallbeck B, Masson G, Shlien A, Palsson ST, Frigge ML, Thorgeirsson TE, Gulcher JR, Stefansson K: A high-resolution recombination map of the human genome. Nat Genet. 2002, 31: 241-247.PubMedGoogle Scholar
- Munafo MR, Thiselton DL, Clark TG, Flint J: Association of the NRG1 gene and schizophrenia: a meta-analysis. Mol Psychiatry. 2006, 11: 613-10.1038/sj.mp.4001840.View ArticleGoogle Scholar
- Corvin AP, Morris DW, McGhee K, Schwaiger S, Scully P, Quinn J, Meagher D, Clair DS, Waddington JL, Gill M: Confirmation and refinement of an 'at-risk' haplotype for schizophrenia suggests the EST cluster, Hs.97362, as a potential susceptibility gene at the Neuregulin-1 locus. Mol Psychiatry. 2004, 9: 208-213. 10.1038/sj.mp.4001412.View ArticlePubMedGoogle Scholar
- Li T, Stefansson H, Gudfinnsson E, Cai G, Liu X, Murray RM, Steinthorsdottir V, Januel D, Gudnadottir VG, Petursson H, Ingason A, Gulcher JR, Stefansson K, Collier DA: Identification of a novel neuregulin 1 at-risk haplotype in Han schizophrenia Chinese patients, but no association with the Icelandic/Scottish risk haplotype. Mol Psychiatry. 2004, 9: 698-704.PubMedGoogle Scholar
- Zhao X, Shi Y, Tang J, Tang R, Yu L, Gu N, Feng G, Zhu S, Liu H, Xing Y, Zhao S, Sang H, Guan Y, St Clair D, He L: A case control and family based association study of the neuregulin1 gene and schizophrenia. J Med Genet. 2004, 41: 31-34. 10.1136/jmg.2003.014977.PubMed CentralView ArticlePubMedGoogle Scholar
- Petryshen TL, Middleton FA, Kirby A, Aldinger KA, Purcell S, Tahl AR, Morley CP, McGann L, Gentile KL, Rockwell GN, Medeiros HM, Carvalho C, Macedo A, Dourado A, Valente J, Ferreira CP, Patterson NJ, Azevedo MH, Daly MJ, Pato CN, Pato MT, Sklar P: Support for involvement of neuregulin 1 in schizophrenia pathophysiology. Mol Psychiatry. 2005, 10: 366-74, 328. 10.1038/sj.mp.4001608.View ArticlePubMedGoogle Scholar
- Yang JZ, Si TM, Ruan Y, Ling YS, Han YH, Wang XL, Zhou M, Zhang HY, Kong QM, Liu C, Zhang DR, Yu YQ, Liu SZ, Ju GZ, Shu L, Ma DL, Zhang D: Association study of neuregulin 1 gene with schizophrenia. Mol Psychiatry. 2003, 8: 706-709. 10.1038/sj.mp.4001377.View ArticlePubMedGoogle Scholar
- Lachman HM, Pedrosa E, Nolan KA, Glass M, Ye K, Saito T: Analysis of polymorphisms in AT-rich domains of neuregulin 1 gene in schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2006, 141: 102-109.View ArticleGoogle Scholar
- Duan J, Martinez M, Sanders AR, Hou C, Krasner AJ, Schwartz DB, Gejman PV: Neuregulin 1 (NRG1 ) and schizophrenia: analysis of a US family sample and the evidence in the balance. Psychol Med. 2005, 35: 1599-1610. 10.1017/S0033291705005428.View ArticlePubMedGoogle Scholar
- Junttila TT, Sundvall M, Maatta JA, Elenius K: Erbb4 and its isoforms: selective regulation of growth factor responses by naturally occurring receptor variants. Trends Cardiovasc Med. 2000, 10: 304-310. 10.1016/S1050-1738(01)00065-2.View ArticlePubMedGoogle Scholar
- Zhang D, Sliwkowski MX, Mark M, Frantz G, Akita R, Sun Y, Hillan K, Crowley C, Brush J, Godowski PJ: Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4. Proc Natl Acad Sci U S A. 1997, 94: 9562-9567. 10.1073/pnas.94.18.9562.PubMed CentralView ArticlePubMedGoogle Scholar
- Harari D, Tzahar E, Romano J, Shelly M, Pierce JH, Andrews GC, Yarden Y: Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase. Oncogene. 1999, 18: 2681-2689. 10.1038/sj.onc.1202631.View ArticlePubMedGoogle Scholar
- Anttila S, Illi A, Kampman O, Mattila KM, Lehtimaki T, Leinonen E: Association of EGF polymorphism with schizophrenia in Finnish men. Neuroreport. 2004, 15: 1215-1218. 10.1097/00001756-200405190-00027.View ArticlePubMedGoogle Scholar
- Watanabe Y, Fukui N, Muratake T, Kaneko N, Someya T: No association of EGF polymorphism with schizophrenia in a Japanese population. Neuroreport. 2005, 16: 403-405. 10.1097/00001756-200503150-00019.View ArticlePubMedGoogle Scholar
- Futamura T, Toyooka K, Iritani S, Niizato K, Nakamura R, Tsuchiya K, Someya T, Kakita A, Takahashi H, Nawa H: Abnormal expression of epidermal growth factor and its receptor in the forebrain and serum of schizophrenic patients. Mol Psychiatry. 2002, 7: 673-682. 10.1038/sj.mp.4001081.View ArticlePubMedGoogle Scholar
- Cohen BD, Green JM, Foy L, Fell HP: HER4-mediated biological and biochemical properties in NIH 3T3 cells. Evidence for HER1-HER4 heterodimers. J Biol Chem. 1996, 271: 4813-4818. 10.1074/jbc.271.9.4813.View ArticlePubMedGoogle Scholar
- Hatakeyama M, Yumoto N, Yu X, Shirouzu M, Yokoyama S, Konagaya A: Transformation potency of ErbB heterodimer signaling is determined by B-Raf kinase. Oncogene. 2004, 23: 5023-5031. 10.1038/sj.onc.1207664.View ArticlePubMedGoogle Scholar
- Riese DJ, van Raaij TM, Plowman GD, Andrews GC, Stern DF: The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol Cell Biol. 1995, 15: 5770-5776.PubMed CentralPubMedView ArticleGoogle Scholar
- Zhang K, Sun J, Liu N, Wen D, Chang D, Thomason A, Yoshinaga SK: Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J Biol Chem. 1996, 271: 3884-3890. 10.1074/jbc.271.7.3884.View ArticlePubMedGoogle Scholar
- Fox IJ, Kornblum HI: Developmental profile of ErbB receptors in murine central nervous system: implications for functional interactions. J Neurosci Res. 2005, 79: 584-597. 10.1002/jnr.20381.View ArticlePubMedGoogle Scholar
- Kornblum HI, Gall CM, Seroogy KB, Lauterborn JC: A subpopulation of striatal gabaergic neurons expresses the epidermal growth factor receptor. Neuroscience. 1995, 69: 1025-1029. 10.1016/0306-4522(95)00392-V.View ArticlePubMedGoogle Scholar
- Carpenter G: ErbB-4: mechanism of action and biology. Exp Cell Res. 2003, 284: 66-77. 10.1016/S0014-4827(02)00100-3.View ArticlePubMedGoogle Scholar
- Hobbs SS, Coffing SL, Le AT, Cameron EM, Williams EE, Andrew M, Blommel EN, Hammer RP, Chang H, Riese DJ: Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activation. Oncogene. 2002, 21: 8442-8452. 10.1038/sj.onc.1205960.View ArticlePubMedGoogle Scholar
- Pinkas-Kramarski R, Shelly M, Guarino BC, Wang LM, Lyass L, Alroy I, Alimandi M, Kuo A, Moyer JD, Lavi S, Eisenstein M, Ratzkin BJ, Seger R, Bacus SS, Pierce JH, Andrews GC, Yarden Y: ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network. Mol Cell Biol. 1998, 18: 6090-6101.PubMed CentralPubMedView ArticleGoogle Scholar
- Gilmore JL, Gallo RM, Riese DJ: The epidermal growth factor receptor (EGFR)-S442F mutant displays increased affinity for neuregulin-2beta and agonist-independent coupling with downstream signalling events. Biochem J. 2006, 396: 79-88. 10.1042/BJ20051687.PubMed CentralView ArticlePubMedGoogle Scholar
- Olayioye MA, Neve RM, Lane HA, Hynes NE: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000, 19: 3159-3167. 10.1093/emboj/19.13.3159.PubMed CentralView ArticlePubMedGoogle Scholar
- NCBI dbSNP website. 2004, http://www.ncbi.nlm.nih.gov/SNP/
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.